Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide for hereditary hemorrhagic telangiectasia with gastrointestinal bleeding
NL-OMON25382Phase 3Not yet recruiting
- Sponsor
- Radboudumc
- Start
- Jan 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hereditary hemorrhagic telangiectasia (HHT) comparing Octreotide plus standard of care with Observation or standard of care (2 arms). Primary endpoint: Successful response. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
octreotide
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NL-OMON25382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25382.